Skip to main content

Our µCPC users report…

Prof. Dr. med. Swaantje Grisanti

µCPC is suitable for young and old to avoid surgery

"Due to its good safety profile and uncomplicated feasibility, µCPC can be used in many patient groups.

We use µCPC in selected cases in younger patients with a clear lens and inadequate IOP control with medication, as well as in older patients in whom intraocular surgery is not possible or desired due to their general condition. The procedure is also suitable for patients with reduced compliance.

Other pressure-lowering interventions in the past or potentially subsequent glaucoma surgery over time are possible. However, the target pressure should not be too low."

University Medical Center Schleswig-Holstein, Lübeck Campus, Clinic for Ophthalmology

Prof.h.c.* Amir-Mobarez Parasta

µCPC as an option after drop therapy has been exhausted – atraumatic and low-risk

"The controllability of µCPC and the lower risk of vitreous opacities make µCPC a very welcome alternative, which we already see as the first option after drip therapy has been exhausted. It does not obstruct any later options and offers a very friendly aftercare profile."


Dr. med. F.E.B.O. Lutz Blomberg

µCPC offers greater pressure reduction than SLT in a gentle procedure

"If SLT does not provide sufficient pressure reduction and the patient is biophakic, µCPC by A.R.C. Laser is a welcome gentle treatment option for mild/moderate PCOWG."

Eye Center Hildesheim-Alfeld

Dr. med. Karsten Paust & Martin Kotula

µCPC offers an early treatment option due to favorable side effect profile

"In our project country Tanzania, A.R.C.-µCPC is a good and, above all, cost-effective and easily accessible treatment option to prevent visual impairment and blindness due to advanced glaucoma in a low-income setting.

The favorable side effect profile also has the potential to make µCPC an earlier treatment option to save even more eyes from irreversible blindness."

TanZanEye Project

Dr. Ute Dibb, FEBO

µCPC is also suitable for advanced glaucoma

"In our setting with many patients with advanced glaucoma, where the options were previously only timolol or trabeculectomy, µCPC is a very welcome alternative. Our patients appreciate the quick and easy treatment, and we are very pleased with the results so far."

Norton Eye Unit, Simbabwe

MD Natalia Palarie

µCPC offers an early treatment option due to favorable side effect profile

My experience with mCPC has been overwhelmingly positive, both from a clinical and patient care perspective. Traditionally, managing IOP in glaucoma patients has been a challenge, often requiring a combination of medication and invasive surgeries. mCPC has offered an effective, minimally invasive alternative that has transformed how we approach glaucoma treatment.
Unlike continuous-wave cyclophotocoagulation, mCPC minimizes collateral tissue damage, reducing post-operative inflammation and discomfort for patients. This has resulted in shorter recovery times and fewer complications, which is a significant advancement in patient care.
From a treatment efficacy standpoint, I have observed substantial and sustained reductions in IOP in many of my patients who have undergone mCPC. This has been particularly beneficial for patients who were either non-responsive to medications or were unable to tolerate them due to side effects.
Another advantage is the repeatability of the procedure. In cases where the IOP begins to creep back up, mCPC can be safely repeated. This flexibility in treatment is invaluable in a progressive condition like glaucoma.
Furthermore, the patient response to mCPC has been extremely positive. Many of my patients express relief and satisfaction with the procedure, noting the ease of the treatment and the improvement in their quality of life. This patient satisfaction is, for me, one of the most rewarding aspects of using this technology.
In summary, mCPC has been a game-changer in glaucoma management. It has enhanced our ability to provide effective, patient-friendly treatment options, thereby improving the quality of life for our patients and advancing the field of ophthalmology.

Nicolae Testemitanu State University of Medicine and Pharmacy

MD, PhD Michele Petitto

µCPC offers high success rates and is repeatable

"My patients that were followed-up for the first 12 months had an initial pressure of approx. 37 mmHg and an IOP reduction between 22.5 and 27 %. In cases where more IOP reduction is needed a retreatment can be conducted after 3 months. In almost 90 % of the cases the IOP have already been achieved the target we have set for each patient. From my experience it is very important to pay attention to the correct speed moving the probe along the bulb and nevertheless the total amount of laser energy applied."

Eye clinic Maracaibo, Venezuela


Dr. Luis Miguel Oviedo Plathi

µCPC reduces pain and the need for medication

"µCPC is a good tool not only for reducing the IOP and pain. I see also the benefit to reduce the amount of eye drops in patients with primary open-angle glaucoma who have vision, ocular surface problems, feeling discomfort or in case of non-compliance in medication. In patients with refractory glaucoma, I have a 50 – 60 % rate of decrease in intraocular pressure." 

University Hospital Maracaibo, Venezuela

Dr. Jorge Galué

µCPC is the gentle and sight-preserving treatment option for glaucoma

"So, we are using the µCPC in many patients; especially in patients where we are looking for a gentle treatment option and in traditional glaucoma patients. Also, in the case of patients with cataracts we combine the µCPC with cataract surgery. So far, we have very good results. Thanks to µCPC we can control our patients, even who have significant nerve injuries at low pressures levels without the need for invasive surgery. The handling of µCPC is easy and after a short learning curve we can give these patients a greater opportunity of preserving vision, even when there is very significant damage."

Eye Clinic Maracaibo, Venezuela